Compare Eureka Prima Jakarta Tbk. (LCGP) vs Merck Tbk. (MERK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eureka Prima Jakarta Tbk. vs Merck Tbk. — how do they compare? Eureka Prima Jakarta Tbk. trades at Rp114 (market cap 641.82B), while Merck Tbk. trades at Rp3,900 (market cap 1.76T, 63K 24h volume). The key difference: Merck Tbk. is far larger — about 2.7× Eureka Prima Jakarta Tbk.'s market cap. Which is the better fit depends on your goals.
| LCGP | MERK | |
|---|---|---|
Market Cap | 641.82B | 1.76T |
Volume | — | 63K |
Lot | — | 630 |
Turnover | — | 243.97M |
Average Price | — | 3,872.46 |
Value | — | 243.97M |
Indicative Equilibrium Price | — | 3,900 |
Indicative Equilibrium Volume | — | 1 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eureka Prima Jakarta Tbk.
PT Eureka Prima Jakarta Tbk formerly Laguna Cipta Griya Tbk (the company) was established based on notarial deed No. 97 dated May 17, 20014 of Bambang Suwondo, S.H., notary in Jakarta and has been amended based on the deed No. 4 dated June 4, 2004 before notary H. Yunardi, S.H. The Company’s articles of association has been amended several times, most recently by notarial deed No. 40 of Fathiah Helmi, S.H., dated Jan 30, 2007, concerning among others, change the company's name.
Read more on LCGP →About Merck Tbk.
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →
